JP Morgan Chase
SBBP

JP Morgan Chase’s Strongbridge Biopharma plc. SBBP Stock Holding History

JP Morgan Chase’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,000
Closed -$6K – 7289
2021
Q3 		$6K Sell
3,000
-3,156
-51% -$7.35K ﹤0.01% 6241
2021
Q2 		$18K Sell
6,156
-117,250
-95% -$310K ﹤0.01% 5952
2021
Q1 		$341K Sell
123,406
-2,875
-2% -$8.68K ﹤0.01% 4897
2020
Q4 		$306K Buy
126,281
+102,106
+422% +$246K ﹤0.01% 4647
2020
Q3 		$51K Sell
24,175
-232,924
-91% -$785K ﹤0.01% 4930
2020
Q2 		$971K Sell
257,099
-165,612
-39% -$496K ﹤0.01% 3532
2020
Q1 		$799K Buy
422,711
+354,945
+524% +$923K ﹤0.01% 3550
2019
Q4 		$142K Buy
67,766
+52,901
+356% +$101K ﹤0.01% 4794
2019
Q3 		$35K Buy
14,865
+1,924
+15% +$5.17K ﹤0.01% 5287
2019
Q2 		$42K Buy
+12,941
New +$47.5K ﹤0.01% 5246
2018
Q2 		– Sell
-7,503
Closed -$66K – 5768
2018
Q1 		$66K Sell
7,503
-9,299
-55% -$69.6K ﹤0.01% 4727
2017
Q4 		$122K Buy
+16,802
New +$105K ﹤0.01% 4588

JP Morgan Chase's SBBP Position: Q4 2021 in Review

JP Morgan Chase sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2021, closing a stake of 3,000 shares — an estimated $6K sold.

JP Morgan Chase first reported a position in SBBP in Q4 2017 and held it in 12 quarters. The position peaked at $971K in Q2 2020. 0 funds tracked by Wall St. Rank hold SBBP as of Q4 2021.

  • JP Morgan Chase reported no remaining Strongbridge Biopharma plc. position as of Q4 2021 after selling out during the quarter.
  • JP Morgan Chase sold 3,000 Strongbridge Biopharma plc. shares in Q4 2021, an estimated $6K.
  • JP Morgan Chase first reported a position in Strongbridge Biopharma plc. in Q4 2017 and held it in 12 quarters.
  • JP Morgan Chase's Strongbridge Biopharma plc. position peaked at $971K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2021.

Based on JP Morgan Chase's 13F filing for Q4 2021, filed 10 Feb 2022.